Holen Sie sich die Stockscreener-App
2.08
0.97%
0.02
Vorhandelsmarkt:
2.08
Schlusskurs vom Vortag:
$2.06
Offen:
$2.1
24-Stunden-Volumen:
557.98K
Relative Volume:
0.77
Marktkapitalisierung:
$69.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.50M
KGV:
-0.52
EPS:
-4
Netto-Cashflow:
$-47.10M
1W Leistung:
-8.37%
1M Leistung:
+21.99%
6M Leistung:
-0.48%
1J Leistung:
-74.42%
1-Tages-Spanne:
$2.04
$2.11
1-Wochen-Bereich:
$2.02
$2.45
52-Wochen-Spanne:
$0.87
$8.70
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Vergleichen Sie OTLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
2.08 | 97.28M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
What analysts say about Outlook Therapeutics Inc. stockDynamic profit expansion - jammulinksnews.com
Outlook Therapeutics Inc. Stock Analysis and ForecastExplosive market performance - jammulinksnews.com
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan
What drives Outlook Therapeutics Inc. stock priceSignificant capital appreciation - Autocar Professional
Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - simplywall.st
Outlook Therapeutics(OTLK) Drops 4.15% Amid Biotech Volatility - AInvest
How Outlook Therapeutics Inc. stock performs during market volatilityCapital Doubling Tips - Newser
Why Outlook Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser
What makes Outlook Therapeutics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser
Outlook Therapeutics (OTLK) Soars 12.08% on Clinical Trial Success - AInvest
Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus PT from Analysts - Defense World
Outlook Therapeutics shares rise 3.12% intraday after recent Federal Circuit's Disclosure-Level Test In In Re Riggs. - AInvest
What caused OTLK's net profit surge in Q3 2024? - AInvest
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
Outlook Therapeutics announces CEO appointment - MSN
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Outlook Therapeutics Appoints New CEO Robert Charles Jahr - The Globe and Mail
Outlook Therapeutics Appoints Bob Jahr as CEO - citybiz
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer | OTLK Stock News - GuruFocus
Outlook Therapeutics, Inc.(NasdaqCM: OTLK) dropped from Russell 2500 Growth Index - MarketScreener
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event | OTLK Stock News - GuruFocus
Outlook Therapeutics, Inc. to Host Virtual Investor Lunch Break Event on June 25, 2025 - Nasdaq
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewswire
Outlook Therapeutics CEO Reveals Commercial Strategy and Key Milestones in Exclusive Investor Event - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook LawsuitOTLK - ACCESS Newswire
Outlook Launches Ophthalmic Bevacizumab In Germany And The UK - insights.citeline.com
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance By Investing.com - Investing.com South Africa
Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com Australia
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus
Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - MarketScreener
Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in Scotland | OTLK Stock News - GuruFocus
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times
Outlook Therapeutics® Announces SMC Recommendation of - GlobeNewswire
Breakthrough: Scotland NHS Approves First-Ever Licensed Bevacizumab Treatment for Wet AMD Patients - Stock Titan
Jane Street Group LLC Purchases 15,008 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):